Breast Cancer
-
Forward Look
Early Chemotherapy Dose Reductions May Affect Breast Cancer OutcomesNew study explores impact of lowering dose due to side effects.
by Jane Langille
-
Cancer Patient Advocates Find Strength in NumbersPatient advocates have become a vital part of the San Antonio Breast Cancer Symposium. Opportunities for advocates continue to multiply.
by Marci A. Landsmann
-
Exploring Immunotherapy for Triple Negative Breast CancerFollowing the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
-
Possible New Treatments for Patients With Metastatic HER2-Positive Breast CancerStudies presented at the San Antonio Breast Cancer Symposium show additional treatment options.
by Marci A. Landsmann
-
A Switch From Intravenous to Oral Chemo?Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.
by Ashley P. Taylor
-
Avoiding Unnecessary Lymph Node BiopsyA study adds to evidence that many patients with ductal carcinoma in situ do not need to have their lymph nodes removed.
by Cheryl Platzman Weinstock
-
Cancer Takes an Unequal Toll on EmploymentIn a study of women with breast cancer in North Carolina, those who lived in rural areas or were black were more likely than urban white women to report negative changes in their employment.
by Pamela Rafalow Grossman
-
Treating Fear of RecurrenceCognitive behavioral therapy may help cancer survivors cope with fear of recurrence, some studies say.
by Jon Kelvey
-
Forward Look
A New Use for Patient DataGregory Daniel on real-world evidence for cancer drug approvals.
by Sue Rochman
-
What to Do About Lymphedema?In a randomized study, weight loss and home-based exercise did not improve lymphedema symptoms in breast cancer survivors.
by Anna Azvolinsky
